CD38-Directed Therapies for Management of Multiple Myeloma

Figures & data

Figure 1 Panel (A) distribution of CD38 across hematopoietic stem cells; Panel (B) mechanism of action of anti-CD38 agents.

Table 1 Selected Trials of Isatuximab in Multiple Myeloma

Clinical Trial	Phase	Setting	Treatment
NCT03617731 (GMMG HD7)	3	Newly diagnosed transplant eligible	Isa+VRD, R maintenance
NCT03319667 (IMROZ)	3	Newly diagnosed transplant ineligible	Isa+VRD
NCT03104842	2	Newly diagnosed high risk	Isa+KRD
NCT02513186	1	Newly diagnosed transplant ineligible	Isa+VCD
NCT04083898	1/2	Relapsed/refractory	Isa+BP
NCT03194867	1/2	Relapsed/refractory	Isa+cemiplimab
NCT02332850	1	Relapsed/refractory	Isa+K

Abbreviations: Isa, isatuximab; VRD, bortezomib, lenalidomide and dexamethasone; KRD, carfilzomib, lenalidomide and dexamethasone; VCD, bortezomib, cyclophosphamide and dexamethasone; BP, Bendamustine and prednisone; K, carfilzomib.